Establishing a framework: Economic evaluations in transfusion medicine, Part 2

Transfusion

Volumn 53, Issue 8, 2013, Pages 1634-1636

  Kacker, Seema ^a   Frick, Kevin D ^a   Tobian, Aaron A R ^b  

^a not available   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD ANALYSIS; BLOOD BANK; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION REACTION; CLINICAL DECISION MAKING; CLINICAL EVALUATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE POLICY; HUMAN; HYPOTHESIS; PROPHYLAXIS; REVIEW; TRANSFUSION;

EID: 84882456239     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12187     Document Type: Review

References (11)

1. Kacker S, Frick KD, Tobian A,. The costs of transfusion: economic evaluations in transfusion medicine, Part 1. Transfusion 2013; 53: 1383-1385.
2. Briggs AH, Claxton K, Sculpher MJ,. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
3. Drummond MF,. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford; New York: Oxford University Press; 2005.
4. Weinstein MC, Torrance G, McGuire A,. QALYs: the basics. Value Health 2009; 12 Suppl 1: S5-9.
5. Custer B,. Economic analyses of blood safety and transfusion medicine interventions: a systematic review. Transfus Med Rev 2004; 18: 127-143.
6. Beliaev AM, Marshall RJ, Gordon M, Smith W, Windsor JA,. Clinical benefits and cost-effectiveness of allogeneic red-blood-cell transfusion in severe symptomatic anaemia. Vox Sang 2012; 103: 18-24.
7. Bell CE, Botteman MF, Gao X, Weissfeld JL, Postma MJ, Pashos CL, Triulzi D, Staginnus U,. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003; 25: 2464-2486.
8. Lopez-Plaza I, Weissfeld J, Triulzi DJ,. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 1999; 39: 925-932.
9. Teljeur C, Flattery M, Harrington P, O'Neill M, Moran PS, Murphy L, Ryan M,. Cost-effectiveness of prion filtration of red blood cells to reduce the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease in the Republic of Ireland. Transfusion 2012; 52: 2285-2293.
10. Kacker S, Ness PM, Savage WJ, Frick KD, McCullough J, King KE, Tobian AA,. The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions. Transfusion 2013. doi: 10.1111/trf.12095
11. Kacker S, Frick KD, Tobian A,. Data and interpretation: economic evaluations in transfusion medicine, Part 4. Transfusion 2013. doi: 10.1111/trf.12185